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Abstract
Background: The suppressive effect of mesenchymal stromal/stem cells (MSCs) on diverse immune cells is well
known, but it is unclear whether MSCs additionally possess immunostimulatory properties. We investigated the
impact of human MSCs on the responsiveness of primary natural killer (NK) cells in terms of cytokine secretion.
Methods: Human MSCs were generated from bone marrow and nasal mucosa. NK cells were isolated from
peripheral blood of healthy volunteers or of immunocompromised patients after severe injury. NK cells were
cultured with MSCs or with MSC-derived conditioned media in the absence or presence of IL-12 and IL-18. C-C
chemokine receptor (CCR) 2, C-C chemokine ligand (CCL) 2, and the interferon (IFN)-γ receptor was blocked by
specific inhibitors or antibodies. The synthesis of IFN-γ and CCL2 was determined.
Results: In the absence of exogenous cytokines, trace amounts of NK cell-derived IFN-γ licensed MSCs for
enhanced synthesis of CCL2. In turn, MSCs primed NK cells for increased release of IFN-γ in response to IL-12 and
IL-18. Priming of NK cells by MSCs occurred in a cell–cell contact-independent manner and was impaired by
inhibition of the CCR2, the receptor of CCL2, on NK cells. CD56bright NK cells expressed higher levels of CCR2 and
were more sensitive to CCL2-mediated priming by MSCs and by recombinant CCR2 ligands than cytotoxic CD56dim
NK cells. NK cells from severely injured patients were impaired in cytokine-induced IFN-γ synthesis. Co-culture with
MSCs or with conditioned media from MSCs and MSC/NK cell co-cultures from healthy donors improved the IFN-γ
production of the patients’ NK cells in a CCR2-dependent manner.
Conclusions: A positive feedback loop driven by NK cell-derived IFN-γ and MSC-derived CCL2 increases the
inflammatory response of cytokine-stimulated NK cells not only from healthy donors but also from
immunocompromised patients. Therapeutic application of MSCs or their soluble factors might thus improve the NK
function after severe injury.
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Background
Mesenchymal stromal/stem cells (MSCs) are nonhema-
topoietic, multipotent progenitor cells that may give rise
to osteoblasts, chondrocytes, and adipocytes. MSCs are
defined according to their lack of the hematopoietic and
endothelial markers CD45 and CD34 and their expres-
sion of the stromal markers CD105, CD90, CD29, and
CD73 [1]. Because of their potential for trilineage differ-
entiation, MSCs are considered to contribute to tissue
regeneration [2]. In addition, MSCs release C-C chemokine
ligand (CCL) 2 (also known as monocyte-chemoattractant
protein MCP-1) that recruits monocytes/macrophages to
the site of injury and, thereby, supports wound healing [3].
MSCs not only possess regenerative capacity but also
display immunomodulatory properties. As part of the
hematopoietic stem cell niche, MSCs are tightly located
to hematopoietic stem cells and are involved in the
maintenance of hematopoiesis [4]. Moreover, MSCs
regulate the function of finally differentiated immune
cells due to the release of regulatory mediators such as
prostaglandin E (PGE) 2, interleukin (IL)-10, or trans-
forming growth factor (TGF)-β [5]. MSCs inhibit the
proliferation of T cells, the release of inflammatory cyto-
kines by dendritic cells and macrophages, the prolifera-
tion and immunoglobulin production of B cells, and the
cytotoxic activity of natural killer (NK) cells [6]. This
regulatory activity of MSCs has led to the development
of novel therapeutic approaches in the treatment of in-
flammatory disorders such as graft-versus-host disease
or autoimmunity. More recently it has been shown that
MSCs do not act as immunosuppressant cells by “de-
fault” but may also enhance inflammation depending on
the microenvironment [7].
NK cells belong to the innate immune system and can
be divided into two subpopulations depending on their
expression of the adhesion molecule CD56 [8]. CD56dim
NK cells are involved in the defense against virus infec-
tions and tumor cells through their cytotoxic activity. In
contrast, CD56bright NK cells possess only poor cytotoxic
activity but release high amounts of interferon (IFN)-γ
upon exposure to the proinflammatory cytokines IL-12
and IL-18, and thereby contribute to effective antimicro-
bial immune responses [9]. From previous in-vitro studies
it is known that MSCs suppress the tumor cell-directed
cytotoxicity, proliferation, and IFN-γ secretion of NK cells
mainly through the release of PGE2 and the activity of
indoleamine 2,3-dioxygenase (IDO) [10]. In contrast to
these reports, we have recently shown that MSCs enhance
the release of IFN-γ from a NK cell line in the context
of stimulation with IL-12 and IL-18. The stimulatory ef-
fect of MSCs on the NK cells occurs in a cell–cell
contact-dependent and contact-independent manner
and is associated with an increased expression of the IL-12
receptor on NK cells [11].
In the present study, we investigated the underlying
mechanism of MSC-mediated NK cell stimulation. We
identified a novel positive feedback loop between MSCs
and primary human NK cells including the release of
CCL2/MCP-1 by MSCs and IFN-γ by NK cells. The
stimulatory activity of MSCs largely affected the
CD56bright NK cell subpopulation. Moreover, MSCs im-
proved the function of NK cells from severely injured
patients who are at enhanced risk for nosocomial infec-




Bone marrow aspirate was obtained from patients who
underwent total hip replacement surgery. Peripheral
blood was drawn from healthy donors and from severely
injured patients on day 8 after injury. The patients were
at least 18 years old, suffered multiple injuries such as
thorax trauma, bone fracture, hemorrhage, brain injury,
or soft tissue trauma, and displayed an Injury Severity
Score (ISS) > 16 (Table 1). Informed consent was ob-
tained from volunteers and from patients or their legal
representatives (in case of unconsciousness). The study
was performed according to the Declaration of Helsinki
and was approved by the Ethics Committee of the Med-
ical Faculty of the University Duisburg-Essen.
Generation of MSCs
Mononuclear cells from bone marrow aspirates were
isolated by density gradient centrifugation using Leuco-
sep tubes (Greiner Bio-One, Frickenhausen, Germany)
according to the manufacturer’s protocol. After washing
with Dulbecco’s Phosphate Buffer Saline (DPBS; Gibco
Life Technologies, Darmstadt, Germany) the cell pellet
was resuspended in “MSC-medium” composed of Dul-
becco’s modified Eagle’s medium (DMEM; Gibco Life
Technologies) supplemented with 10 % endotoxin-tested
fetal calf serum (FCS; Biochrome, Berlin, Germany), 100
U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-gluta-
max, and 1 mM sodium pyruvate (all from Sigma,
Deisenhofen, Germany). One million mononuclear cells
were seeded in 7 ml MSC-medium per T75 cm2 flask
(Greiner Bio-One) and were incubated in a humidified
atmosphere containing 5 % CO2 at 37 °C. After 24 h,
Table 1 Characteristics of healthy donors and patients
Controls Patients
(n = 6) (n = 6)
Age (years) 32 (22–37) 25 (21–45)
Gender (male/female) 2/4 4/2
ISS – 36 (34–43)
Age and Injury Severity Score (ISS) are expressed as median (25th–75th
interquartile range)
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half of the medium was replaced by fresh MSC-medium.
Forty hours later, the nonadherent cells were removed
by gentle washing with phosphate-buffered saline (PBS;
Gibco Life Technologies) before addition of MSC-
medium. Thereafter, the medium was replaced twice a
week. When the cells reached a confluency of around
80 % they were detached using 6 ml Accutase (Gibco
Life Technologies), harvested, and reseeded at 106 cells
per flask (T75 cm2) in 7 ml MSC-medium. After three
passages, phenotypical characterization was performed
by flow cytometry [1]. All MSCs were negative for the
hematopoietic or endothelial markers CD45, CD34, and
CD31 but expressed the characteristic MSC markers
CD29, CD73, CD90, and CD105 (see Additional file 1:
Figure S1). MSCs were used in passages 3–8 throughout
the experiments. MSCs from nasal mucosa (nmMSCs)
were generated as described previously [13]. MSCs from
five bone marrow aspirate donors and from three nasal
mucosa donors were used in this study.
Isolation of mononuclear cells and NK cells from blood
Peripheral blood mononuclear cells (PBMC) were ob-
tained from peripheral blood density gradient centrifuga-
tion as already described. Untouched NK cells were
isolated from PBMC using a negative selection human
NK cell isolation kit with AutoMACS (both from Milte-
nyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instruction. The purity of CD56+ NK
cells was >90 % as determined by flow cytometry. NK
cells were cultured in “NK cell-medium” Very Low
Endotoxin medium VLE RPMI-1640 (Biochrome) sup-
plemented with 10 % FCS, 100 U/ml penicillin, 0.1 mg/
ml streptomycin, and 2 mML-glutamax (all from
Sigma). Purified NK cells were directly used for the ex-
periments. NK cells from 27 healthy donors and from
six patients were used in this study.
Cell culture
MSCs were seeded at 1.25 × 104 cells per well (24-well
plate; BD Biosciences, Heidelberg, Germany) in 900 μl
MSC-medium. The medium was aspirated after over-
night culture and 6.25 × 104 NK cells in 900 μl NK cell-
medium were added. As controls, MSCs and NK cells
were cultured alone in NK cell-medium. In parallel, cell-
free NK cell-medium was incubated under identical con-
ditions. In one experimental set-up, NK cells were
placed in a 24-well trans-well plate (0.4 μm pore size;
BD Biosciences) with MSCs on the bottom of the cul-
ture plate. After 24 h, the cultures underwent one of the
following three procedures: “co-culture”, NK cell mono-
cultures and MSC/NK cell co-cultures were stimulated
with IL-12 (1 ng/ml; Miltenyi Biotec) and IL-18 (10 ng/ml;
MBL International, Woburn, MA, USA); “detachment”,
NK cells from mono-cultures and NK cells that were
detached from MSCS in the co-cultures were harvested
by gentle pipetting, washed, and replated in fresh wells
(1 × 104 NK cells/well, 96-well plate; BD Biosciences)
before stimulation with IL-12 (1 ng/ml) and IL-18
(10 ng/ml); and “conditioned media”, supernatants from
MSCs alone, NK cells alone, MSC/NK cell-co-cultures,
and the cell-free medium were harvested and served as
“conditioned media” after removal of residual cells by
centrifugation. The conditioned media (150 μl) were im-
mediately transferred to freshly isolated NK cells that
were seeded at 1 × 104 per well (96-well plate) in 50 μl
NK cell-medium. Thereafter, the cells were stimulated
with IL-12 (1 ng/ml) and IL-18 (10 ng/ml) or left un-
stimulated as a negative control.
Alternatively, freshly isolated NK cells (1 × 104 per well;
96-well plate) were cultured in the presence or absence of
recombinant human CCL2/MCP-1, CCL8, CCL7, or
CCL12 (all from PeproTech, Hamburg, Germany) at a
final concentration of 0.5 ng/ml for 12 h before stimula-
tion with IL-12 (1 ng/ml) and IL-18 (5 ng/ml).
Where specified, neutralizing monoclonal antibodies
against CCL2/MCP-1 (clone 2H5; BioXCell, West
Lebanon, NH, USA), unspecific hamster IgG isotype
control antibodies (each 10 μg/ml; BioXCell), inhibitory
monoclonal antibodies against the IFN-γ receptor 1
(clone GIR208; Biotechne, Wiesbaden, Germany), un-
specific mouse IgG1 isotype control antibodies (each
10 μg/ml; Biotechne), a selective antagonist of the C-C-
chemokine receptor (CCR) 2 (RS102895, 5 nM; Tocris
Bioscience, Bristol, UK), or dimethyl sulfoxide (DMSO;
Sigma) as solvent control were added to the cultures. In
general, all cultures were set up in 4–5 replicates. Cell
supernatants were harvested 24 h after stimulation with
IL-12 and IL-18 and were stored at –20 °C.
In a separate set of experiments, MSCs were seeded as
already described and treated with different concentrations
of recombinant human IFN-γ (5–100 pg/ml; Miltenyi
Biotec) or with PBS as control for 12 h before superna-
tants were harvested.
Quantification of CCL2/MCP-1 and IFN-γ
Quantification of human CCL2/MCP-1 and IFN-γ was
performed by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(DuoSet; Biotechne). The detection limit was 15 pg/ml.
For some analyses, a specialized highly sensitive IFN-γ
ELISA with a detection limit of 1.6 pg/ml was used ac-
cording to the manufacturer’s instructions (NBP1-91174
Interferon gamma; Novus Biologics/Biotechne).
Flow cytometry
PBMC were incubated with fluorescent antibodies
against CD3 (fluorescein isothiocyanate-labeled, clone
DaA3; Immuno Tools, Friesoythe, Germany), CD56
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(allophycocyanin-labeled, clone CMSSB; eBioscience,
San Diego, CA, USA), and CD192/CCR2 (phycoeryth-
rin-labeled, clone K036C2; Biolegend, San Diego, CA,
USA) for 12 min at 4 °C. Thereafter, the cells were
washed with Cell Wash (BD Biosciences).
For intracellular detection of IFN-γ in NK cells, 0.5 μl/
ml of Golgi-Stop (Monensin; BD Biosciences) was added
during the last 5 h of culture. After surface staining
using anti-CD3 and anti-CD56 antibodies as already de-
scribed, the cells were fixed and permeabilized using
Cytofix/Cytoperm (BD Biosciences) and antibodies
against IFN-γ (phycoerythrin-labeled, clone 4S.B3; Biole-
gend) were added. After 20 min, the cells were washed.
Appropriate isotype controls were used for all stain-
ings. The acquisition of data was performed using
FACSCalibur (BD Biosciences). Data were analyzed
using Cell Quest Pro software (BD Biosciences). NK cells
were identified and gated as CD3–CD56bright or CD3–
CD56dim cells. The expression of CCR2 and IFN-γ on/in
gated NK cells was quantified according to the isotype
control staining.
Statistical analyses
Data from replicate cultures are presented as mean ± SD
in bar graphs and statistical analysis was performed
using one-way ANOVA followed by the Bonferroni mul-
tiple comparison test. Combined data of multiple donors
are presented as scatter plots and median with inter-
quartile range. Statistical analysis was performed using
the Mann–Whitney U test or Wilcoxon signed-rank test
as indicated. GraphPad Prism 5.0 served as the software
for the analyses. p ≤ 0.05 was considered statistically
significant.
Results
MSCs prime NK cells for increased IFN-γ secretion
We have previously shown that human bone marrow-
derived MSCs prime NK-92 cells, a human NK cell line,
for increased release of IFN-γ upon stimulation with IL-
12 and IL-18. We investigated whether MSCs similarly
modulated human primary NK cells from peripheral
blood and whether the presence of MSCs during stimu-
lation of NK cells with cytokines was required to exert
their stimulatory effect on NK cells. Therefore, human
primary NK cells were isolated from peripheral blood of
healthy donors and were cultured alone or together with
MSCs at a ratio of 5:1 (NK cells:MSCs) for 24 h before
stimulation with IL-12 and IL-18. At this ratio MSCs
displayed an intermediate stimulatory effect on NK cells
as verified previously [11]. Unstimulated cells served as
negative controls. In the absence of IL-12 and IL-18, NK
cells did not release detectable levels of IFN-γ (Fig. 1a).
As expected, NK cells released IFN-γ after exposure to
IL-12 and IL-18. In the presence of MSCs, IFN-γ secre-
tion by NK cells increased by 2-fold (Fig. 1a).
To address the relevance of MSCs during stimulation
of NK cells, mono-cultures and co-cultures were set up.
After 24 h, NK cells were carefully harvested, washed,
and transferred into fresh culture plates before stimula-
tion. NK cells that had been co-cultured with MSCs and
then separated released significantly higher levels of
IFN-γ than NK cells that had been cultured alone
(Fig. 1b). No IFN-γ was released from reseeded NK cells
in the absence of IL-12 and IL-18 (Fig. 1b).
Because contact with MSCs during stimulation of NK
cells with IL-12 and IL-18 was not required to increase
the release of IFN-γ, we next investigated whether sol-
uble factor(s) derived from MSCs were responsible for
the priming effect on NK cells. Therefore, “conditioned
media” from NK cells alone, MSCs alone, and MSC/NK
cell co-cultures were harvested and transferred to freshly
isolated NK cells. Transfer of cell-free medium that had
been kept under identical conditions to the cells was
used as control. Thereafter, the NK cells were stimulated
or left unstimulated. In the presence of conditioned
medium from MSCs alone and, even more, from MSC/
NK cell co-cultures, NK cells released significantly in-
creased amounts of IFN-γ upon stimulation (Fig. 1c).
The conditioned medium from NK cell mono-cultures
did not change the IFN-γ production (Fig. 1c). Condi-
tioned media did not induce the secretion of IFN-γ from
NK cells in the absence of IL-12 and IL-18 (Fig. 1c).
Intracellular staining and flow cytometry revealed that
CD56bright NK cells were the main subpopulation that
secreted IFN-γ upon stimulation (Fig. 1d). Thus, MSCs
instruct primary NK cells for increased IL-12/IL-18-in-
duced IFN-γ secretion through a soluble factor.
MSC-derived CCL2/MCP-1 mediates NK cell priming
We determined the content of CCL2/MCP-1 in the con-
ditioned media from mono-cultures and co-cultures that
had been prepared as already described. No CCL2/
MCP-1 was detectable in the supernatant from NK cells.
As expected, MSCs alone released CCL2/MCP-1
(Fig. 2a). When co-cultured with NK cells, MSCs re-
leased more CCL2/MCP-1 (Fig. 2a). The extent of CCL2
secretion varied depending on the combination of MSCs
and NK cells (Fig. 2b). To evaluate whether CCL2/MCP-
1 might contribute to the MSC-mediated priming of NK
cells for increased IFN-γ synthesis, we first investigated
whether NK cells expressed CCR2, the receptor for
CCL2/MCP-1. CD56bright NK cells expressed CCR2 at
much higher levels than CD56dim NK cells (Fig. 2c). We
observed a large variation in CCR2 expression between
different donors (Fig. 2d).
Next, we investigated the priming of NK cells by
MSCs in the presence of neutralizing antibodies against
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CCL2/MCP-1. Mono-cultures and co-cultures were
therefore set up in the presence or absence of neutraliz-
ing antibodies against CCL2/MCP-1 before stimulation.
Neutralization of CCL2/MCP-1 reduced the secretion of
IFN-γ in MSC/NK cell co-cultures but not in cultures of
NK cells alone (Fig. 3a, b). In the absence of IL-12 and
IL-18, NK cells did not secrete detectable levels of IFN-γ
(data not shown).
We asked whether CCL2/MCP-1 likewise contributed
to the stimulatory activity of the conditioned media
when transferred to fresh NK cells. Neutralization of
CCL2/MCP-1 completely and partially abrogated the
stimulatory effect of the conditioned media from MSCs
and from MSC/NK cell co-cultures, respectively (Fig. 3c,
d).
Likewise, inhibition of CCR2, the receptor for CCL2,
with the specific inhibitor RS102895 clearly decreased
the release of IFN-γ from NK cells when co-cultured to-
gether with MSCs but not when cultured alone (Fig. 4a,
b). Moreover, inhibition of CCR2 completely reversed
the stimulatory effect of the conditioned medium from
MSCs on the NK cell-derived IFN-γ production and
clearly decreased the priming that was mediated by con-
ditioned medium from MSC/NK cell co-cultures (Fig. 4c,
Fig. 1 MSCs prime NK cells for increased IFN-γ release. a, b Purified NK cells from healthy volunteers were cultured in the absence (NK) or presence of
MSCs (MSC/NK) for 24 h. a Cells were stimulated with IL-12 (1 ng/ml) and IL-18 (10 ng/ml). Unstimulated cells served as negative control. Twenty-four
hours later, the content of IFN-γ in the supernatants was determined. b NK cells were harvested, washed, transferred into fresh plates, and stimulated
or not with IL-12 and IL-18. The content of IFN-γ in the supernatants was quantified after 24 h. c Freshly isolated NK cells were cultured in the presence
of conditioned media (CM) from NK cells, MSCs, MSC/NK cell co-cultures, and cell-free medium and were stimulated with IL-12 and IL-18. The
release of IFN-γ into the supernatant was determined 24 h later. Bar graphs show mean ± SD of 4–5 replicates from one representative out of at
least 12 independent experiments. Statistical analysis was performed using one-way ANOVA followed by Bonferroni multiple comparison test.
d Flow cytometric analysis of intracellular IFN-γ synthesis in gated CD3–CD56bright and CD3–CD56dim NK cells stimulated with IL-12 and IL-18.
Unstimulated cells served as negative control (–). The threshold of positive staining for IFN-γ was set according to the isotype control (iso).
Numbers in the dot plots show the percentage of cells positive for IFN-γ. The median (interquartile range) of the percentage of IFN-γ+ cells
among CD56bright NK cells was 58.3 (55.6–67; n = 7). **p < 0.01, ***p < 0.001. MSC mesenchymal stromal/stem cell, NK natural killer, IFN interferon
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d). In the absence of IL-12 and IL-18, NK cells did not
secrete detectable levels of IFN-γ (data not shown).
In order to investigate whether the NK cell-
stimulatory activity was specific for bone marrow-
derived MSCs we additionally used nmMSCs in the
same experimental set-up. Upon contact with NK cells,
nmMSCs strongly increased their release of CCL2
(Fig. 4e). In turn, the contact with nmMSCs stimulated
NK cells for enhanced IL-12/IL-18-induced secretion of
IFN-γ in a CCR2-dependent manner (Fig. 4f ).
Having established that CCR2 and its ligand CCL2/
MCP-1 contributed to the MSC-mediated priming of
Fig. 2 MSCs increase the release of CCL2 upon contact with NK cells and CD56bright NK cells express CCR2. a, b Conditioned media (CM) from NK
cells, MSCs, MSC/NK cell co-cultures, and cell-free medium were prepared as described in Methods and the content of CCL2 was quantified. a Bar
graph showing mean ± SD of 4–5 replicates from one representative experiment. b Cumulative data of 15 experiments. No CCL2 was detectable
in CM from NK cells only. Statistical analysis was performed using one-way ANOVA followed by Bonferroni multiple comparison test. c, d PBMC
were stained with fluorochrome-labeled antibodies against CD3, CD56, and CCR2. c Representative dot plot of CCR2 expression on gated
CD3–CD56bright and CD3–CD56dim NK cells (gated as shown in Fig. 1d). Numbers indicate the percentage of cells positive for CCR2. The threshold
of positive staining for CCR2 was set according to the isotype control (iso). d Scatter plot showing the percentage of CCR2+ cells among
CD56bright and CD56dim NK cells from individual healthy donors (n = 27). Horizontal lines indicate the median with interquartile range. Statistical
analysis was performed using the Wilcoxon signed-rank test. ***p < 0.001. MSC mesenchymal stromal/stem cell, NK natural killer, CCL2 C-C chemokine
ligand 2, CCR2 C-C chemokine receptor 2
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NK cells, we asked whether targeting CCR2 was a
general mechanism that stimulates NK cells for en-
hanced release of IFN-γ. In addition to CCL2/MCP-1
there exist several ligands of CCR2, namely CCL8/
MCP-2, CCL7/MCP-3, and CCL12/MCP-5. NK cells
were therefore cultured in the presence or absence of
diverse CCR2 ligands before stimulation at subopti-
mal levels in order to detect the synergism between
the recombinant chemokines and IL-12/IL-18. As
control, NK cells were treated with the CCR2 ligands
alone. All ligands increased the IL-12/IL-18-induced
release of IFN-γ (Fig. 5a). None of the ligands in-
duced the release of IFN-γ in the absence of IL-12
and IL-18 (Fig. 5a). Intracellular staining revealed that
the CCR2 ligands similar to conditioned medium
from MSCs increased the percentage of IFN-γ-
producing CD56bright NK cells upon exposure to IL-
12 and IL-18 (Fig. 5b, c). In contrast, CD56dim NK
cells did not respond to the CCR2 ligands or to the
conditioned medium (Additional file 2: Figure S2).
Thus, CCL2/MCP-1 is released by MSCs and MSC/
NK cell co-cultures and stimulates CD56bright NK
cells for increased IL-12/IL-18-induced IFN-γ synthe-
sis in a CCR2-dependent manner.
NK cell-derived IFN-γ licenses MSCs for increased CCL2/
MCP-1 release
Considering that MSCs released enhanced amounts of
CCL2/MCP-1 when cultured in the presence of NK cells
under neutral conditions (Fig. 2a) we asked whether NK
cells in turn stimulated MSCs through IFN-γ. Therefore,
mono-cultures and co-cultures were set up in the pres-
ence of antibodies that blocked the IFN-γ receptor. No
further cytokines were added. Moreover, co-cultures
were set up in a trans-well system that allows the ex-
change of soluble factors but prevents direct cell-to-cell
contact. The content of IFN-γ was determined using a
highly sensitive ELISA. No IFN-γ was detected in super-
natants from MSCs alone (Fig. 6a). IFN-γ was present at
very low levels in MSC/NK cell co-cultures independent
of the cell contact (Fig. 6a). Blocking of the IFN-γ recep-
tor led to the accumulation of IFN-γ in all MSC/NK cell
co-cultures but not in MSC mono-cultures (Fig. 6a).
Quantification of CCL2/MCP-1 in the same superna-
tants revealed that the constitutive release of CCL2/
MCP-1 by MSCs was not affected by blocking the IFN-γ
receptor. In contrast, the increased synthesis of CCL2/
MCP-1 in the MSC/NK cell co-cultures was completely
abrogated in the presence of the anti-IFN-γ receptor
Fig. 3 Neutralization of CCL2 diminishes the MSC-mediated stimulation of NK cells. a, b NK cells were incubated alone or in co-culture with MSCs
in the presence of neutralizing antibodies against CCL2 or isotype control antibodies for 24 h. Thereafter, the cells were stimulated with IL-12 and
IL-18 for 24 h and the concentration of IFN-γ in the supernatants was determined. b Freshly isolated NK cells were incubated with conditioned
media (CM) from NK cells, MSCs, MSC/NK cell co-cultures, and cell-free medium each in the presence of neutralizing antibodies against CCL2 or
the isotype control. Thereafter, all cells were stimulated with IL-12 and IL-18 for 24 h. The amount of IFN-γ in the supernatant was quantified.
a, c Bar graphs showing mean ± SD of 4–5 replicates of one representative experiment. Statistical analysis was performed using one-way ANOVA
followed by Bonferroni multiple comparison test. b, d Cumulative and normalized data of eight independent experiments. One hundred percent
was equivalent to median (interquartile range) 132 (70–340) pg/ml and 87 (38–308) pg/ml in (b) and (d), respectively. Statistical analysis was
performed using the Wilcoxon signed-rank test. *p < 0.05**p < 0.01***p < 0.001. MSC mesenchymal stromal/stem cell, NK natural killer, CCL2 C-C
ligand 2, IFN interferon
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antibodies (Fig. 6b). The separation of MSCs and NK
cells during culture did not change the NK cell-
mediated increase of CCL2/MCP-1 production or the
suppressive effect of the anti-IFN-γ receptor antibodies
on the synthesis of CCL2/MCP-1 (Fig. 6b).
To confirm that such a low amount of IFN-γ as found
in the MSC/NK cell co-cultures was able to increase the
release of MSC-derived CCL2/MCP-1, MSCs were cul-
tured with low concentrations of recombinant IFN-γ.
We observed that as little as 5 pg/ml IFN-γ was suffi-
cient to significantly increase the release of CCL2/MCP-
1 by MSCs (Fig. 6c). Thus, under neutral conditions NK
cell-derived IFN-γ licenses MSCs for increased CCL2/
MCP-1 production.
MSC-derived CCL2/MCP-1 improves the function of NK
cells of immunocompromised patients
Next, we asked whether MSCs exert their stimulatory
capacity not only under physiological conditions but
also under pathological conditions that are associated
with suppressed NK cell function. We have evidence
that NK cells from critically ill patients after major in-
jury and surgery are impaired in function [14, 15]. In a
small pilot study, we investigated the IFN-γ release
from NK cells isolated from patients after severe injury
and evaluated whether it was modulated by MSCs from
healthy individuals. NK cells from critically ill patients
and from healthy donors (for characteristics see Table 1)
were therefore stimulated with IL-12 and IL-18. NK
Fig. 4 Inhibition of CCR2 attenuates the MSC-mediated activation of NK cells. a, b NK cells were treated with the CCR2 inhibitor RS102895 or with
the solvent DMSO as control before they were cultured alone or in co-culture with MSCs for 24 h. Thereafter, the cells were stimulated with IL-12
and IL-18 and the supernatant was harvested after 24 h for quantification of IFN-γ. c, d Freshly isolated NK cells were treated with the CCR2 inhibitor
RS102895 or with DMSO as control before addition of conditioned media (CM) from NK cells, MSCs, MSC/NK cell co-cultures, and cell-free
medium. Thereafter, all cells were stimulated with IL-12 and IL-18 and the amount of IFN-γ in the supernatants was quantified. a, c Bar graphs
showing mean ± SD of 4–5 replicates of one representative experiment. b, d Cumulative and normalized data of 4–5 independent experiments.
One hundred percent was equivalent to median (interquartile range) 352 (285–386) pg/ml and 723 (371–816) pg/ml in (b) and (d), respectively.
e CCL2 content in conditioned media from mono-cultures and co-cultures using MSCs from human nasal mucosa. f IFN-γ release from NK cells
cultured alone or together with MSCs from human nasal mucosa each in the presence or absence of RS102895. Bar graphs showing mean ± SD
of 4–5 replicates of one representative out of three independent experiments. Statistical analysis was performed using one-way ANOVA
followed by Bonferroni multiple comparison test. ***p < 0.001. CCL2 C-C ligand 2, DMSO dimethyl sulfoxide, MSC mesenchymal stromal/stem
cell, NK natural killer, IFN Interferon
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Fig. 5 Monocyte chemotactic proteins promote IFN-γ production in
NK cells. NK cells were incubated in the absence (–) or presence of
recombinant human CCL2, CCL8, CCL7, and CCL12, or with conditioned
medium (CM) from MSCs for 12 h. Thereafter, the cells were stimulated
with suboptimal concentrations of IL-12 (1 ng/ml) and IL-18 (5 ng/ml)
or left unstimulated. a After 24 h the content of IFN-γ in the
supernatant was determined. Bar graph showing mean ± SD of 4–5
replicates of one representative out of five independent experiments.
Statistical analysis was performed using one-way ANOVA followed by
Bonferroni multiple comparison test. b Dot plots of intracellular
staining of IFN-γ in gated CD3–CD56bright NK cell (gating strategy as
shown in Fig. 1d) after stimulation with IL-12 and IL-18. The threshold
of positive staining for IFN-γ was set according to the isotype control
(iso). Numbers indicate the percentage of IFN-γ-positive NK cells. c
Cumulative data on the percentage of IFN-γ+CD56bright NK cells from
five donors after normalization to the percentage of cells stimulated
with IL-12/IL-18 in the absence of CCL (set as 100 %). Vertical lines
indicate the median and interquartile range. ***p < 0.001, **p < 0.01.
CCL C-C chemokine ligand, IFN interferon, MSC mesenchymal
stromal/stem cell
Fig. 6 NK cell-derived IFN-γ enhances the CCL2 production from
MSCs. a, b MSCs were treated with blocking antibodies against the
receptor for IFN-γ (IFN-γR) or with isotype control antibodies. NK cells
were added directly to the MSCs or were separated by a trans-well. After
24 h, the concentration of IFN-γ (a) and CCL2 (b) in the supernatants
was quantified. c MSCs were cultured with various concentrations of
recombinant human IFN-γ for 12 h and the production of CCL2 was
measured. Bar graphs showing mean ± SD of 3–5 replicates from one
representative out of three experiments. Statistical analysis was
performed using one-way ANOVA followed by Bonferroni multiple
comparison test. ***p < 0.001, **p < 0.01, *p< 0.05. MSC mesenchymal
stromal/stem cell, NK natural killer, CCL2 C-C ligand 2, IFN interferon
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cells from patients released much less IFN-γ than NK
cells from control subjects (Fig. 7a). The synthesis of
IFN-γ was increased when the patients’ NK cells were
cultured together with MSCs (Fig. 7b, c). The stimula-
tory effect of MSCs on these NK cells was partially
inhibited by neutralization of CCL2/MCP-1 (Fig. 7b, c).
Moreover, the stimulatory effect of conditioned media
from cells of healthy donors on NK cells from severely
injured patients was evaluated. Conditioned medium
from MSCs and from MSC/NK cell co-cultures of
healthy donors increased the IL-12/IL-18-induced IFN-γ
secretion from the patients’ NK cells in a CCL2/MCP-1-
dependent manner (Fig. 7d). Overall, the stimulatory ac-
tivity of conditioned media from MSCs and MSC/NK
co-cultures on the patients’ NK cells was 2-fold and 3.3-
fold, respectively (Fig. 7e). In the absence of IL-12 and
IL-18, the patients’ NK cells did not release detectable
levels of IFN-γ (data not shown). The CCL2/MCP-1-
mediated activity of MSCs is thus not restricted to NK
cells under homeostasis but also seems to be applicable
to NK cells that are suppressed in function due to crit-
ical illness.
Fig. 7 NK cells from severely injured patients exhibit impaired IFN-γ production, which is partially rescued by MSC-derived CCL2. a Purified NK
cells from healthy donors and severely injured patients (n = 6) were stimulated with IL-12 and IL-18 for 24 h and the concentration of IFN-γ in the
supernatants was determined. Horizontal lines indicate the median with interquartile range. b, c MSCs were treated with neutralizing antibodies
against CCL2 or with the isotype control. Purified NK cells from patients were added to MSCs from healthy donors or were cultured alone. All cells
were stimulated with IL-12 and IL-18 for 24 h and the concentration of IFN-γ in the supernatants was assessed. b Bar graph showing mean ± SD
of 5 replicates from one representative experiment. c Scatter plot showing the individual values obtained from cells of six patients. Data were
normalized to the values from NK cells alone stimulated in the presence of the isotype control (set as 100 %). Horizontal lines indicate the median
with interquartile range. d, e NK cells isolated from patients were treated with conditioned media (CM) from NK cells, MSCs, MSC/NK cell
co-cultures (all from healthy controls), and cell-free medium each in the presence of neutralizing antibodies against CCL2 or the isotype control.
Thereafter, all cells were stimulated with IL-12 and IL-18. The release of IFN-γ into the supernatant was determined 24 h later. d Bar graph
showing mean ± SD of 4 replicates from one representative experiment. e Scatter plot showing individual values obtained from NK cells of six
patients. Data were normalized to the values from NK cells treated with “medium” (Med) and stimulated in the presence of the isotype control
(set as 100 %). Horizontal lines indicate the median with interquartile range. Statistical analysis was performed using the Mann–Whitney U test (a),
one-way ANOVA followed by Bonferroni multiple comparison test (b, d) or Wilcoxon signed-rank test (c, e). ***p < 0.001, **p < 0.01, *p < 0.05. MSC
mesenchymal stromal/stem cell, NK natural killer, CCL2 C-C ligand 2, IFN interferon
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Discussion
The majority of studies on the immunomodulatory ac-
tivity of MSCs report the inhibitory effect of MSCs on
diverse cells of the immune system. The key factors in
human MSC-mediated immunoregulation are IDO,
PGE2, and TGF-β [5]. There exist only few reports on
proinflammatory properties of MSCs that deal with the
attraction and stimulation of granulocytes or macro-
phages [16, 17]. We have previously identified another
proinflammatory activity of MSCs because they increase
the production of IL-12 and IL-18-induced IFN-γ from
NK-92 cells through unknown mechanisms [11]. We
show here that MSCs exerted their stimulatory activity
also on human primary NK cells during cell–cell contact
as well as through a soluble factor. In line with previous
reports, the minor CD56bright NK cell population was
superior in IL-12/IL-18-induced IFN-γ production com-
pared with the CD56dim NK cell subtype [18]. Accord-
ingly, the MSC-mediated stimulation of NK cells was
more apparent in CD56bright NK cells. Overall, we ob-
served a broad range of the amount of CCL2 and IFN-γ
that was released from MSCs and NK cells from differ-
ent donors, respectively. A donor-dependent variation of
the size of the CD56bright NK cell population among
total NK cells might contribute to the diverse IFN-γ pro-
duction of the NK cells. The finding that conditioned
medium from MSC/NK cell co-cultures was more po-
tent in NK cell stimulation than conditioned medium
from MSCs alone indicates that an immunostimulatory
factor was released during the interaction of MSCs and
NK cells.
Mechanistically, we identified chemokine receptor
CCR2 and its ligand CCL2/MCP-1 as the major compo-
nents in the MSC-mediated stimulation of NK cells.
MSCs constitutively secrete CCL2/MCP-1 and other
chemokines [19]. CCR2, the receptor for CCL2/MCP-1,
is expressed on diverse immune cells, such as mono-
cytes/macrophages, dendritic cells, T cells, and NK cells.
CCL2/MCP-1 so far seemed to contribute to the im-
munosuppressive properties of MSCs. MSC-derived
CCL2/MCP-1 attracts macrophages to tumors and
thereby promotes tumor growth [20]. Likewise, murine
T cells are recruited by MSC-derived CCL2/MCP-1 and
subsequently are suppressed by NO that is released into
the microenvironment by murine MSCs [21]. In addition
to its chemotactic activity, MSC-derived CCL2/MCP-1
directly modulates cellular functions of target cells, such
as the immunoglobulin production by plasma cells and
the inhibition of Th17 T cells [22, 23].
In line with a previous study we observed that
CD56bright NK cells displayed a stronger expression of
the CCR2 than CD56dim NK cells [24]. The knowledge
on the impact of CCL2/MCP-1 on NK cells is largely
restricted to its chemotactic properties [24, 25]. We
provide the novel finding that MSC-derived CCL2/
MCP-1 directly acts on resting CD56bright NK cells that
subsequently respond to IL-12 and IL-18 with an in-
creased production of IFN-γ. The weak expression of
the CCR2 on CD56dim NK cells might explain why
MSCs do not promote but rather reduce the low pro-
duction of IFN-γ from CD56dim NK cells when exam-
ined immediately after stimulation [26]. The finding that
blocking of CCL2/MCP-1 in conditioned media from
MSCs/NK cell co-cultures was less effective than inhib-
ition of the CCR2 on NK cells led to the assumption that
CCL2/MCP-1 was not the only factor which triggered
CCR2 on CD56bright NK cells. Indeed, alternative ligands
of CCR2—namely CCL7, CCL8, and CCL12—displayed
similar stimulatory activity on CD56bright NK cells and
might also have been present in the conditioned media
from MSCs.
It remains unclear how CCL2/MCP-1-mediated signal-
ing interacts with the IL-12/IL-18-induced pathway in
CD56bright NK cells. Activation of suppressor of cytokine
signaling 3 (SOCS3) and suppression of T-box expressed
in T cells (T-bet) were identified as mechanistic targets
of CCL2 secreted from decidual stromal cells on diverse
leukocytes [19, 27]. However, transcription of the ifng
gene requires the expression of T-bet and is suppressed
by SOCS3 [28–30]. Therefore, we assume that signaling
pathways distinct to activation of SOCS3 and suppres-
sion of T-bet are induced in CD56bright NK cells after ex-
posure to MSC-derived CCL2 in order to increase their
IFN-γ response.
Several studies in the past have shown that MSCs re-
quire licensing by exogenously added IFN-γ and tumor
necrosis factor alpha or by specific toll-like receptor li-
gands to acquire immunosuppressive effects [31–34]. In
our study, the interaction of MSCs and NK cells oc-
curred in the absence of exogenous proinflammatory or
anti-inflammatory factors. Minute amounts of IFN-γ
that were produced in the MSC/NK cell co-cultures
were sufficient to further drive the release of CCL2/
MCP-1 from MSCs, indicating that NK cells licensed
MSCs in the neutral environment. On the contrary, the
bidirectional interaction with MSCs primed NK cells in
a CCR2-dependent manner for increased IFN-γ secre-
tion upon exposure to IL-12 and IL-18. This immunosti-
mulatory feedback loop between MSCs and NK cells
represents a novel aspect in the plasticity of MSC
function.
NK cells maintained their enhanced responsiveness to
IL-12 and IL-18 even after detachment from MSCs and
removal of MSC-derived factors. This is in contrast to
the well-studied MSC-mediated suppression of T-cell re-
sponsiveness that requires a closer vicinity between
MSCs and T cells as the immunosuppressive factors NO
and IDO act only over a short distance [21, 35].
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Transferred to a potential in-vivo situation, we speculate
that, after priming by MSCs, CD56bright NK cells may
support inflammation both locally and distant to the site
of MSC encounter; for example, upon infection that is
associated with the release of IL-12 and IL-18 [36, 37]. It
is important to note that MSC-derived CCL2/MCP-1
per se did not induce the release of IFN-γ from NK cells.
Thus, it is unlikely that MSCs cause uncontrolled in-
flammation in the absence of, for example, an infectious
insult. Moreover, considering the importance of NK cell-
derived IFN-γ in T-helper cell polarization in lymphoid
organs, such MSC-primed NK cells might favor the
development of inflammatory T-helper cell type 1 re-
sponses [38]. Further studies are required to evaluate the
existence and the consequences of MSC-mediated NK
cell priming in vivo, especially under the view of the
growing number of clinical studies based on the thera-
peutic application of MSCs.
The administration of anti-inflammatory MSCs in
clinical trials has so far been aimed largely at treating
hyperinflammatory diseases such as graft-versus-host
disease and autoimmunity [39, 40]. Because of their in-
hibitory properties the use of MSCs in diseases associ-
ated with immunodeficiency has so far been regarded as
contraindicative. Severe injuries or invasive surgical in-
terventions cause a state of immunosuppression [12].
These patients suffer from nosocomial infections that
may result in life-threatening septic shock. The under-
lying pathomechanisms of injury-induced immunosup-
pression are not yet fully understood and protective
therapies are warranted. We have presented evidence
that NK cells from severely injured patients are impaired
in IFN-γ production upon exposure to Staphylococcus
aureus [14]. In line with these data, we show here for
the first time that NK cells from severely injured pa-
tients are suppressed in their capacity to secrete IFN-γ
in response to IL-12/IL-18, the key cytokines in the
defense against diverse pathogens. We observed that
MSCs from healthy donors at least partially restored the
suppressed IFN-γ synthesis of NK cells from such pa-
tients. Moreover, conditioned media from MSCs as well
as from co-cultures of MSCs and NK cells from healthy
donors clearly improved the IFN-γ release from NK cells
of injured patients. Similar to our data obtained from
NK cells from healthy donors, CCL2/MCP-1 mediated
the stimulatory effect of MSCs and their conditioned
media on the patients’ NK cells.
Conclusions
In the neutral environment, trace amounts of NK cell-
derived IFN-γ licensed MSCs for enhanced release of
CCL2/MCP-1 that primed NK cells for increased secre-
tion of IFN-γ upon exposure to IL-12 and IL-18. This
novel positive feedback loop between MSCs and NK
cells was not only observed for NK cells from healthy
donors but also for NK cells from immunocompromised
patients. Targeting MSCs or their soluble factors to the
patients’ NK cells might improve the immune function
after severe injury and, thereby, extend the indication of
MSC therapy.
Additional files
Additional file 1: Figure S1. Expression of specific molecules on
MSCs. MSCs were incubated with fluorochrome-labeled antibodies
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histograms show the fluorescence of the isotype (grey shaded area)
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Additional file 2: Figure S2. CD56dim NK cells do not respond to CCR2
ligands. NK cells were incubated in the absence (–) or presence of
0.5 ng/ml of recombinant human CCL2, CCL8, CCL7, and CCL12, or with
conditioned medium (CM) from MSCs for 12 h. Thereafter, the cells were
stimulated with IL-12 (1 ng/ml) and IL-18 (5 ng/ml). Dot plots of intracel-
lular staining of IFN-γ in gated CD3–CD56dim NK cells (gating strategy as
shown in Fig. 1d). Data are representative for one out of five experiments.
The threshold of positive staining for IFN-γ was set according to the isotype
control (iso). Numbers indicate the percentage of IFN-γ-positive NK cells.
MSC mesenchymal stromal/stem cell, CCL C-C ligand, IFN interferon.
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